Trust Co. of Toledo NA OH Acquires 502 Shares of Becton, Dickinson and Company (NYSE:BDX)

Trust Co. of Toledo NA OH grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.0% during the first quarter, Holdings Channel reports. The institutional investor owned 1,593 shares of the medical instruments supplier’s stock after purchasing an additional 502 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Becton, Dickinson and Company were worth $365,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 6.5% during the 1st quarter. Brighton Jones LLC now owns 1,885 shares of the medical instruments supplier’s stock worth $432,000 after acquiring an additional 115 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Becton, Dickinson and Company by 431.7% during the first quarter. Exchange Traded Concepts LLC now owns 19,848 shares of the medical instruments supplier’s stock valued at $4,546,000 after purchasing an additional 16,115 shares during the period. Foster Victor Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the first quarter worth approximately $6,406,000. Ritholtz Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth $224,000. Finally, Dynamic Advisor Solutions LLC raised its holdings in Becton, Dickinson and Company by 7.7% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 1,406 shares of the medical instruments supplier’s stock valued at $322,000 after buying an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Richard Byrd sold 459 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now owns 6,952 shares of the company’s stock, valued at $1,598,960. This trade represents a 6.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares of the company’s stock, valued at $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,104 shares of company stock valued at $399,675 in the last three months. Company insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of recent analyst reports. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price target on the stock. in a report on Friday, May 2nd. Raymond James cut Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research note on Friday, May 2nd. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Wells Fargo & Company lowered Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Finally, Morgan Stanley decreased their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $219.22.

Becton, Dickinson and Company Stock Down 1.4%

BDX stock opened at $172.06 on Monday. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company has a market capitalization of $49.31 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.25. The business’s 50 day moving average price is $183.03 and its two-hundred day moving average price is $212.95. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.17 earnings per share. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.42%. Becton, Dickinson and Company’s payout ratio is 79.39%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.